Roffman Miller Associates’s Biogen BIIB Stock Holding History

Roffman Miller Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,055	Closed	-$282K	–	83
2020 Q2	$282K	Buy	+1,055	New	+$317K	0.03%	122

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Roffman Miller Associates's BIIB Position: Q3 2020 in Review

Roffman Miller Associates sold out of Biogen (BIIB) in Q3 2020, closing a stake of 1,055 shares — an estimated $282K sold.

Roffman Miller Associates first reported a position in BIIB in Q2 2020 and held it in 1 quarter. The position peaked at $282K in Q2 2020. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

Roffman Miller Associates reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
Roffman Miller Associates sold 1,055 Biogen shares in Q3 2020, an estimated $282K.
Roffman Miller Associates first reported a position in Biogen in Q2 2020 and held it in 1 quarter.
Roffman Miller Associates's Biogen position peaked at $282K in Q2 2020.
1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on Roffman Miller Associates's 13F filing for Q3 2020, filed 6 Nov 2020.